TRIAZOLE DERIVATIVES AS P2Y14 RECEPTOR ANTAGONISTS


The technology describes the composition of small molecule compounds that are antagonists of the P2Y14 receptor. Also provided are methods of using the compounds, including a method of treating a disorder, such as inflammation, diabetes, insulin resistance, hyperglycemia, a lipid disorder, obesity, a condition associated with metabolic syndrome, and asthma, and a method of antagonizing P2Y14 receptor activity in a cell.

Potential Commercial Applications: Competitive Advantages:
  • Development of P2Y14 receptor antagonist for treatment of disorders, such as:
  • Inflammation
  • diabetes
  • obesity
  • asthma
  • lipid disorder
  • metabolic syndromer
 


Inventors:

Kenneth Jacobson (NIDDK)  ➽ more inventions...

Evgeny Kiselev (NIDDK)  ➽ more inventions...

Elisa Uliassi (NIDDK)  ➽ more inventions...

Anna Junker (NIDDK)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 10,683,277 issued 2020-06-16
PCT Application No. PCT/US16/053397
US Application No. 15/762,852

Publications:
Junker A, et al, Structure-based design of 3-(4-aryl-1H-1,2,3-triazol-1-yl)-biphenyl derivatives as P2Y14 receptor antagonists. J. Med. Chem., 2016, 59:6149−6168. https://dx.doi.org/10.1021/acs.jmedchem.6b00044

Collaboration Opportunity:

The NIDDK is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize TRIAZOLE DERIVATIVES AS P2Y14 RECEPTOR ANTAGONISTS. For collaboration opportunities, please contact Kenneth A. Jacobson, Ph.D. at ,a href="mailto:kennethj@niddk.nih.gov">kennethj@niddk.nih.gov


Licensing Contact:
Betty Tong, Ph.D.
Email: tongb@niddk.nih.gov
Phone: 301-451-7836

OTT Reference No: E-213-2015-0
Updated: Nov 20, 2020